Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Oct 11 2018

• By Jessica Merrill

Insulin ampoule and a syringe isolated against white background

Related Content

VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching

Oct 10 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

FDA Makes It Official With Basaglar Approval For Diabetes

Dec 16 2015

Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?

Oct 02 2018

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Aug 01 2017

Related Companies

Merck & Co., Inc.

Sanofi

Samsung Bioepis Co., Ltd.

Eli Lilly and Company

Johnson & Johnson

Pfizer Inc.

Boehringer Ingelheim GmbH

Viatris Inc.

Additional Topics

United States Biosimilars Strategy Launches Business Strategies Commercial Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window